News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Marcia F. T. Rupnow, PhD

Articles by Marcia F. T. Rupnow, PhD

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

ByRobert A. Bailey, MD,Ujjwala Vijapurkar, PhD,Gary E. Meininger, MD,Marcia F. T. Rupnow, PhD,Lawrence Blonde, MD

December 16th 2014

Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

ByVarun U. Ektare, BPharm, MPH,Janice M. S. Lopez, PharmD, MPH,Silas C. Martin, MS,Dipen A. Patel, BPharm, PhD,Marcia F. T. Rupnow, PhD,Marc F. Botteman, MSc, MA

October 26th 2014

Participating Faculty: Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

ByVarun U. Ektare, BPharm, MPH,Janice M. S. Lopez, PharmD, MPH,Silas C. Martin, MS,Dipen A. Patel, BPharm, PhD,Marcia F. T. Rupnow, PhD,Marc F. Botteman, MSc, MA

October 26th 2014

Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin

ByRobert A. Bailey, MD,C. V. Damaraju, PhD,Silas C. Martin, MS,Gary E. Meininger, MD,Marcia F. T. Rupnow, PhD,Lawrence Blonde, MD

January 25th 2014

Latest Updated Articles

Participating Faculty: Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
October 26th 2014
Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus
October 26th 2014
Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
December 16th 2014
Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin
January 25th 2014

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies